Anales de la RANM

262 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 ESTENOSIS AÓRTICA: PASADO, PRESENTE Y PERSPECTIVAS FUTURAS An RANM. 2025;142(03): 255 - 262 Albaladejo Muñoz B, et al. 2012;366(18):1686–1696. doi:10.1056/NEJ- Moa1200384. 17. Forrest JK, Makkar RR, Yakubov SJ, et al. Four- year outcomes from the Evolut Low Risk trial. J Thorac Cardiovasc Surg. 2024;[Epub ahead of print]. doi:10.1016/j.jtcvs.2024.08.023. 18. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk pa- tients. N Engl J Med. 2019;380(18):1695–1705. doi:10.1056/NEJMoa1814052. 19. Landes U, Holzmann J, Witberg G, et al. Temporal trends, outcomes, and predictors of structural valve deterioration after trans- catheter aortic valve replacement. Circulation. 2021;143(6):602–612. doi:10.1161/CIRCULA- TIONAHA.120.049756. 20. Pibarot P, Ternacle J, Jaber WA, et al. Dura- bility of transcatheter bioprosthetic aortic valves. Eur Heart J. 2019;40(25):2235–2239. doi:10.1093/eurheartj/ehz162. 21. Jilaihawi H, Asch FM, Manasse E, et al. Pa- ravalvular leak after TAVR: understanding, prevention, and management. J Am Coll Cardiol. 2019;73(3):295–314. doi:10.1016/j. jacc.2018.09.085. 22. Rodés-Cabau J, Ellenbogen KA, Krahn AD, et al. Conduction disturbances after trans- catheter aortic valve implantation: current status and future perspectives. Circulation. 2019;139(24):2253–2269. doi:10.1161/CIRCU- LATIONAHA.118.035521. 23. Baron SJ, Magnuson EA, Lu M, et al. Cost- effectiveness of transcatheter versus surgical aortic valve replacement in intermediate-risk patients. J Am Coll Cardiol. 2019;73(20):2600– 2612. doi:10.1016/j.jacc.2019.02.057. 24. Praz F, Borger MA, Lanz J, et al.; ESC/EACTS Scientific Document Group. 2025 ESC/ EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2025 Aug 29:ehaf194. doi:10.1093/eurheartj/ehaf194. 25. Kappetein AP, Head SJ, Généreux P, et al. Up- dated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-3. Eur Heart J. 2021;42(19):1825–1857. doi:10.1093/ eurheartj/ehaa409. 26. Yoon SH, Bleiziffer S, De Backer O, et al. Outco- mes of transcatheter aortic valve replacement in bicuspid aortic valve stenosis. J Am Coll Cardiol. 2021;77(2):148–59. doi:10.1016/j. jacc.2020.10.058. 27. Leon MB, Mack MJ, Hahn RT, et al. Outco- mes of transcatheter aortic valve replacement in patients with chronic kidney disease: a re- view. J Am Coll Cardiol. 2021;77(1):110–123. doi:10.1016/j.jacc.2020.11.024. 28. Kaiser Y, Singh SS, Newby DE, Dweck MR. Lipoprotein(a) is associated with onset but not progression of aortic valve calcification. Eur Heart J. 2022;43(39):3960–3967. doi:10.1093/ eurheartj/ehac377. 29. Mirzai S, Block RC, et al. A randomized, double-blind, placebo-controlled, multicen- ter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS] (ClinicalTrials. gov NCT05646381). [Internet]. Clinical- Trials.gov. 2024 [cited 2025 Aug 31]. Availa- ble from : h ttps://clinicaltrials.gov/ct2/show/ NCT05646381. 30. Raposeiras-Roubín S, Amat-Santos IJ, Rosse- lló X, et al. Dapagliflozin in patients under- going transcatheter aortic-valve implantation. N Engl J Med. 2025 Mar 29 [Epub ahead of print]. doi:10.1056/NEJMoa2500366. 31. Chung J, Tong J, Mehta C, Moss RR. Arti- ficial intelligence and machine learning in valvular heart disease: current status and fu- ture prospects. Heart. 2023;109(7):565–572. doi:10.1136/heartjnl-2022-321821. 32. Otto CM, Pibarot P, Hahn RT, et al. Perso- nalized medicine in aortic stenosis: integra- ting imaging, biomarkers, and artificial inte- lligence. Circulation. 2022;146(9):687–700. doi:10.1161/CIRCULATIONAHA.121.055123. Si desea citar nuestro artículo: Albaladejo Muñoz B, Zamorano Gómez JL. Estenosis aór- tica: pasado, presente y perspectivas futuras. An RANM. 2025;142(03): 255– 262. DOI: 10.32440/ar.2025.142.03. rev04